A Case of COVID mRNA Vaccine Linked Antiphospholipid Syndrome
Biomedical Science and Clinical Research · 2023
DOI: 10.33140/bscr.02.01.13 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Science and Clinical Research, 2023.
Abstract (Originalsprache)
Introduction: There have been several reports of thrombotic adverse events after administration of the mRNA Covid vaccine [1, 2]. The onset of autoimmune disease has also been reported following viral illness as well as following vaccination [3]. Antiphospholipid syndrome (APS) is an autoimmune hypercoagulable state that can result in thrombotic events such as deep venous thrombosis, pulmonary embolus, and stroke [4]. Antiphospholipid antibodies (aPLs) are associated with APS syndrome. However, not all individuals with aPLs will develop antiphospholipid syndrome as antiphospholipid antibodies are also present in up to 5% of the healthy population. Antiphospholipid antibodies have been reported after infections and vaccines. Antiphospholipid syndrome has also been reported following natural Covid infection [5]. Herein we present a case of antiphospholipid syndrome following Covid mRNA vaccination associated with life-threatening thrombosis, dyspnea, and hypoxia coupled with multiple adverse reactions affecting skin, respiratory, nervous, and vascular systems.
Zitieren
APA
(2023). A Case of COVID mRNA Vaccine Linked Antiphospholipid Syndrome. Biomedical Science and Clinical Research. https://doi.org/10.33140/bscr.02.01.13
Vancouver
A Case of COVID mRNA Vaccine Linked Antiphospholipid Syndrome. Biomedical Science and Clinical Research. 2023. doi:10.33140/bscr.02.01.13
BibTeX
@article{euvimed2023,
title = {A Case of COVID mRNA Vaccine Linked Antiphospholipid Syndrome},
journal = {Biomedical Science and Clinical Research},
year = {2023},
doi = {10.33140/bscr.02.01.13}
}
EUVIMED